Management of residual symptoms and re-entry

The manuals converge on the need to prepare participants for residual or delayed effects after the main session, and to frame these experiences in a non-alarming way. Across the extracts, the sources recommend explaining that reactivations, flashbacks, or brief recurrence of symptoms may happen after the session, and they emphasise reassurance, monitoring, and guidance if delayed effects become troubling. They also overlap on practical re-entry safeguards. The manuals recommend attention to sleep and home support, with the LSD handbook specifically noting bedtime recurrence, overnight therapist contact, transport home, no driving, and someone staying awake until sleep if the person is an outpatient. The later sources similarly stress continued observation into the post-acute period and discharge only when the participant is stable and safe. The main differences are in emphasis and time frame. The 5-MeO-DMT sources focus more on ongoing sensitivity, possible reverberation after the session, and the possibility that meditation or practice may access the state again, while the 2022 review places more weight on monitoring reactivations and flashbacks over the days to 1 to 2 weeks after exposure. The 2023 trial report is the most general, concentrating on delayed adverse effects such as headaches, fatigue, mood changes, and flashback-like experiences, rather than on the specific re-entry arrangements described in the older LSD manual.